Patents by Inventor Khalid Shah

Khalid Shah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10285993
    Abstract: A novel crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection are disclosed. In some embodiments, the novel crystalline form comprises a stable polymorph of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate. The present invention is further directed to a process for the preparation of the novel crystalline form.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: May 14, 2019
    Assignee: Array BioPharma Inc.
    Inventors: Alisha B. Arrigo, Derrick Juengst, Khalid Shah
  • Publication number: 20190030021
    Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, Cl, or X2 is H, Br, Cl, or n1 is 1-2; and n2 is 1-2.
    Type: Application
    Filed: October 4, 2018
    Publication date: January 31, 2019
    Inventors: Jo Ann Wilson, Khalid Shah
  • Publication number: 20190016767
    Abstract: Described herein are novel compositions comprising multimodal TRAIL agents and cells engineered to express such multimodal TRAIL agents, including cells encapsulated in a scaffold or matrix, for use in the treatment of disorders such as cancer.
    Type: Application
    Filed: June 21, 2018
    Publication date: January 17, 2019
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventor: Khalid Shah
  • Patent number: 10172861
    Abstract: A novel crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection are disclosed. In some embodiments, the novel crystalline form comprises a stable polymorph of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate. The present invention is further directed to a process for the preparation of the novel crystalline form.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: January 8, 2019
    Assignee: Array BioPharma Inc.
    Inventors: Alisha B. Arrigo, Derrick Juengst, Khalid Shah
  • Patent number: 10130680
    Abstract: The technology described herein is directed to methods and compositions directed to the treatment of cancer, e.g. using multifunctional receptor targeted cancer therapeutics.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: November 20, 2018
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventor: Khalid Shah
  • Publication number: 20180311229
    Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.
    Type: Application
    Filed: July 3, 2018
    Publication date: November 1, 2018
    Inventors: Jo Ann Wilson, Khalid Shah
  • Publication number: 20180303877
    Abstract: Embodiments herein provide engineered mammalian cells, compositions comprising these cells and methods for targeted cancer therapy using cytotoxins derived from Pseudonomas sp. Specifically, it relates to cell-based, targeted in vivo delivery of Pseudonomas exotoxin (PE) for cancer therapy.
    Type: Application
    Filed: September 25, 2015
    Publication date: October 25, 2018
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventor: Khalid Shah
  • Patent number: 10039757
    Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound I are disclosed.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: August 7, 2018
    Assignee: Exelixis, Inc.
    Inventors: Jo Ann Wilson, Khalid Shah
  • Patent number: 10034873
    Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound I are disclosed.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: July 31, 2018
    Assignee: Exelixis, Inc.
    Inventors: Jo Ann Wilson, Khalid Shah
  • Publication number: 20180207162
    Abstract: A novel crystalline form of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection are disclosed. In some embodiments, the novel crystalline form comprises a stable polymorph of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate. The present invention is further directed to a process for the preparation of the novel crystalline form.
    Type: Application
    Filed: January 16, 2018
    Publication date: July 26, 2018
    Inventors: Alisha B. Arrigo, Derrick Juengst, Khalid Shah
  • Patent number: 10030057
    Abstract: Described herein are novel compositions comprising multimodal TRAIL agents and cells engineered to express such multimodal TRAIL agents, including cells encapsulated in a scaffold or matrix, for use in the treatment of disorders such as cancer.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: July 24, 2018
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventor: Khalid Shah
  • Publication number: 20180148694
    Abstract: Disclosed herein is a recombinant oncolytic virus comprising a nucleic acid sequence encoding tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). One such oncolytic virus is oHSV. One form of TRAIL contained within the oncolytic virus is a secreted form of TRAIL. Examples of various forms of oHSV and secreted TRAIL are disclosed therein. Also disclosed are host cells and therapeutic formulations comprising the recombinant oncolytic virus. Also disclosed are methods of treating cancer in a subject by administering a therapeutic formulation comprising the recombinant oncolytic virus to the subject.
    Type: Application
    Filed: December 5, 2017
    Publication date: May 31, 2018
    Applicant: The General Hospital Corporation
    Inventors: Khalid Shah, Kaoru Tamura, Hiroaki Wakimoto
  • Publication number: 20180112006
    Abstract: Compositions and methods are provided comprising soluble TRAIL polypeptide agents and cells engineered to express such agents for the treatment of multifocal brain metastases.
    Type: Application
    Filed: April 15, 2016
    Publication date: April 26, 2018
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventor: Khalid SHAH
  • Publication number: 20180021342
    Abstract: A novel crystalline form of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection are disclosed. In some embodiments, the novel crystalline form comprises a stable polymorph of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate. The present invention is further directed to a process for the preparation of the novel crystalline form.
    Type: Application
    Filed: September 15, 2017
    Publication date: January 25, 2018
    Inventors: Alisha B. Arrigo, Derrick Juengst, Khalid Shah
  • Patent number: 9862932
    Abstract: Disclosed herein is a recombinant oncolytic virus comprising a nucleic acid sequence encoding tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). One such oncolytic virus is oHSV. One form of TRAIL contained within the oncolytic virus is a secreted form of TRAIL. Examples of various forms of oHSV and secreted TRAIL are disclosed therein. Also disclosed are host cells and therapeutic formulations comprising the recombinant oncolytic virus. Also disclosed are methods of treating cancer in a subject by administering a therapeutic formulation comprising the recombinant oncolytic virus to the subject.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 9, 2018
    Assignee: The General Hospital Corporation
    Inventors: Khalid Shah, Kaoru Tamura, Hiroaki Wakimoto
  • Patent number: 9782414
    Abstract: A novel crystalline form of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection are disclosed. In some embodiments, the novel crystalline form comprises a stable polymorph of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate. The present invention is further directed to a process for the preparation of the novel crystalline form.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: October 10, 2017
    Assignee: Array BioPharma, Inc.
    Inventors: Alisha B. Arrigo, Derrick Juengst, Khalid Shah
  • Publication number: 20170266178
    Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound I are disclosed.
    Type: Application
    Filed: June 2, 2017
    Publication date: September 21, 2017
    Inventors: Jo Ann Wilson, Khalid Shah
  • Patent number: 9724342
    Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound I are disclosed.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: August 8, 2017
    Assignee: Exelixis, Inc.
    Inventors: Jo Ann Wilson, Khalid Shah
  • Patent number: 9717720
    Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: August 1, 2017
    Assignee: Exelixis, Inc.
    Inventors: Jo Ann Wilson, Khalid Shah
  • Publication number: 20170165267
    Abstract: A novel crystalline form of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection are disclosed. In some embodiments, the novel crystalline form comprises a stable polymorph of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate. The present invention is further directed to a process for the preparation of the novel crystalline form.
    Type: Application
    Filed: January 5, 2017
    Publication date: June 15, 2017
    Inventors: Alisha B. Arrigo, Derrick Juengst, Khalid Shah